106 results on '"Martinelli, Giovanni"'
Search Results
2. Earthquake geochemical scientific expedition and research
3. Personalizing precision medicine: Patients with AML perceptions about treatment decisions
4. Geochemical features and seismic imaging of the tectonic zone between the Tibetan Plateau and Ordos Block, central northern China
5. Effects of yoga practice on physiological distress, fatigue and QOL in patients affected by breast cancer undergoing adjuvant radiotherapy
6. Geochemical and geophysical effects of tectonic activity in faulted areas of the North China Craton
7. CometAnalyser: A user-friendly, open-source deep-learning microscopy tool for quantitative comet assay analysis
8. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.
9. An SDN-enabled multi-layer protection and restoration mechanism
10. Factors constraining the geographic distribution of earthquake geochemical and fluid-related precursors
11. On the possible origin of thermal infrared radiation (TIR) anomalies in earthquake-prone areas observed using robust satellite techniques (RST)
12. Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study.
13. c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration
14. CML-182: SETD2 Loss of Function Induces Genomic Instability in CML and May Contribute to Disease Progression to Blast Crisis.
15. Laboratory measurements on radon exposure effects on local environmental temperature: Implications for satellite TIR measurements.
16. Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National Registry.
17. New targets for Ph+ leukaemia therapy.
18. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
19. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels.
20. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years
21. MM-415: Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma.
22. MM-409: Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pre-Treated Multiple Myeloma: Old/New in the Novel Agents' Era.
23. MM-418: Pegfilgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Pomalidomide-Based Treatment.
24. AML-091: Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib.
25. ALL-132: Ponatinib Versus Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia: (ALL): PhALLCON Study.
26. Poster: MM-418: Pegfilgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Pomalidomide-Based Treatment.
27. Poster: MM-415: Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma.
28. Poster: MM-409: Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pre-Treated Multiple Myeloma: Old/New in the Novel Agents' Era.
29. Poster: CML-182: SETD2 Loss of Function Induces Genomic Instability in CML and May Contribute to Disease Progression to Blast Crisis.
30. Poster: AML-091: Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib.
31. Poster: ALL-132: Ponatinib Versus Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): PhALLCON Study.
32. Resistance to Tyrosine Kinase Inhibitors in Philadelphia Chromosome–Positive Leukemias: Which Mutations Matter?
33. Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pretreated Multiple Myeloma: Old/New in Novel Agents' Era.
34. Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma.
35. Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) – Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial
36. Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML).
37. First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients
38. Mechanochemical dissociation of calcium carbonate: laboratory data and relation to natural emissions of CO2
39. Long-range correlation analysis of earthquake-related geochemical variations recorded in Central Italy
40. Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma.
41. Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment With Pomalidomide-Dexamethasone.
42. Ponatinib vs Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) ALL: PhALLCON Study.
43. Tyrosine Kinase Inhibitors (TKI) in Relapsed/Refractory (RR) Patients with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Confer Better Survival than Chemotherapy, Due to a Better Safety Profile.
44. Age, Disease Status before Blinatumomab, MRD Negativity Obtainment, and Bridge to Transplant Influence Outcome in Patients with B-ALL: A Single Center Experience.
45. Impact of Arterial Thrombotic Events on the Outcome of Chronic Myeloid Leukemia Patients Treated with Nilotinib First-Line: A GIMEMA CML WP Analysis.
46. Evolutionary Fitness of Relapsed Multiple Myeloma Patients Who Responded to Upfront Combination Therapy Including New Drugs.
47. A More Mature Immunophenotypic Make-up of Multiple Myeloma Clone(s) at Diagnosis Correlates With a Higher Genomic Instability.
48. Blinatumomab is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: the Bologna Compassionate Program Experience.
49. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
50. “Pieve Santo Stefano” is not a mud volcano: Comment on “Structural controls on a carbon dioxide-driven mud volcano field in the Northern Apennines” (by Bonini, 2009)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.